BioLineRx (BLRX) Begins Phase 1/2a Study of GLIX1 for Glioblastoma Treatment

First patient dosed in the GLIX1 glioblastoma trial today. First in human history for this mechanism. Led by Dr. Roger Stupp, the researcher who wrote the current standard of care for GBM in 2005. Three world class cancer centers enrolling patients.

$BLRX has a $12 million market cap. Phase 1 data expected H1 2027.

$MRNA $BIIB $REGN $VRTX #biotech #GBM #oncology #braintumor